Advertisement

Urologic Cancer

  • Tomio Inoue
  • Nobukazu Takahashi
  • Tetsuya Higuchi
  • E. Edmund Kim
Chapter

Abstract

Positron emission tomography (PET) is a unique imaging modality with the capability of studying regional metabolism. 18F-fluoro-deoxyglucose (FDG) is the most widely used tracer in the field of PET oncology. The clinical utility of oncology PET using FDG has been proven in the staging and restaging of malignant tumors such as those in the head/neck, lung, breast, and colorectal cancers, as well as malignant lymphoma and melanoma. In the field of urology, FDG PET has been evaluated for relevant malignancies with promising results in certain areas and disappointing results in others. At present, FDG PET is capable of visualizing urologic tumors and associated lymph nodes and distal metastatic sites. However, its use is severely limited by excretion of the most commonly used radioisotope via the urinary tract, making pelvic imaging particularly unrewarding. 11C-choline, up-regulated in malignant cells, has shown potential usefulness in brain, prostate, and esophageal cancers with enhanced synthesis of membrane phospholipids. This chapter discusses the clinical usefulness of oncology PET in the field of urology, including renal cell, urinary bladder, and prostate cancer, as well as testicular tumors. We review the related articles of PET oncology in the field of urology.

Keywords

Positron Emission Tomography Renal Cell Carcinoma Bladder Cancer Positron Emission Tomography Imaging Renal Cell Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Khandani AH, Rathmell WK. Positron emission tomography in renal cell carcinoma: an imaging ­biomarker in development. Semin Nucl Med. 2012;42(4):221–30.PubMedCrossRefGoogle Scholar
  2. 2.
    Safei A, Figlin R, Hoh CK, et al. The usefulness of F-18 deoxyglucose whole-body positron emission tomography (PET) for restaging of renal cell cancer. Clin Nephrol. 2002;57:56–62.Google Scholar
  3. 3.
    Poggi MM, Patronas N, Buttman JA, et al. Intramedullary spinal cord metastasis from renal cell carcinoma: detection by positron emission tomography. Clin Nucl Med. 2001;26:837–9.PubMedCrossRefGoogle Scholar
  4. 4.
    See WA, Fuller JR. Staging of advanced bladder cancer. Current concepts and pitfalls. Urol Clin North Am. 1992;19:663–83.PubMedGoogle Scholar
  5. 5.
    Ahlstrom H, Malmstrom PU, Letocha H, et al. Positron emission tomography in the diagnosis and staging of urinary bladder cancer. Acta Radiol. 1996;37:180–5.PubMedGoogle Scholar
  6. 6.
    Heicappell R, Muller-Mattheis V, Reinhardt M, et al. Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 2-[(18)F]-2-deoxy-D-glucose. Eur Urol. 1999;36:582–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Hara T, Kosaka M, Kishi H. PET imaging of brain tumor with [methyl-11C] choline. J Nucl Med. 1997;38:842–7.PubMedGoogle Scholar
  8. 8.
    Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med. 1998;39:990–5.PubMedGoogle Scholar
  9. 9.
    Inoue T, Oriuchi N, Tomiyoshi K, et al. A shifting landscape: what will be next FDG in PET oncology? Ann Nucl Med. 2002;16:1–9.PubMedCrossRefGoogle Scholar
  10. 10.
    DeGrado TR, Baldwin SW, Wang S, et al. Synthesis and evaluation of F-18 labeled choline analogs as oncologic PET tracers. J Nucl Med. 2001;42:1805–14.PubMedGoogle Scholar
  11. 11.
    Park H, Wood D, Hussain H, et al. Introducing parametric fusion PET/MRI of primary prostate cancer. J Nucl Med. 2012;53(4):546-51.PubMedGoogle Scholar
  12. 12.
    Schuster DM, Votaw JR, Nieh PT, et al. Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med. 2007;48(1):56-63.PubMedGoogle Scholar
  13. 13.
    Kitajima K, Nakamoto Y, Senda M, et al. Ann Nucl Med. 2007;21(7):405–10.PubMedCrossRefGoogle Scholar
  14. 14.
    Spermon JR, De Geus-Oei LF, Kiemeney LA, et al. The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and restaging after chemotherapy for testicular germ cell tumours. BJU Int. 2002;89:549–56.PubMedCrossRefGoogle Scholar
  15. 15.
    De Santis M, Bokemeyer C, Becherer A, et al. Predictive impact of 2-18-fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma. J Clin Oncol. 2001;19:3740–4.PubMedGoogle Scholar
  16. 16.
    Tsatalpas P, Beuthien-Baumann B, Kropp J, et al. Diagnostic value of F-18 FDG positron emission tomography for detection and treatment control of malignant germ cell tumors. Urol Int. 2002;68:157–63.PubMedCrossRefGoogle Scholar
  17. 17.
    Cremerious U, Effert PJ, Adam G, et al. FDG PET for detection and therapy control of metastatic germ cell tumor. J Nucl Med. 1998;39:815–22.Google Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Tomio Inoue
    • 1
  • Nobukazu Takahashi
    • 1
  • Tetsuya Higuchi
    • 2
  • E. Edmund Kim
    • 3
    • 4
  1. 1.Department of RadiologyYokohama City University Graduate School of MedicineYokohamaJapan
  2. 2.Department of Nuclear Medicine and Diagnostic RadiologyGumma University School of MedicineMaebashiJapan
  3. 3.Departments of Nuclear Medicine and Diagnostic RadiologyThe University of Texas MD Anderson Cancer Center and Medical SchoolHoustonUSA
  4. 4.Graduate School of Convergence Science and TechnologySeoul National UniversitySeoulSouth Korea

Personalised recommendations